Financing
Proceeds from issuance of warrants
Year-over-year, this metric declined by 100.0%, from $23.86M to $0.00. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementCash Flow Statement
SectionFinancing
CategoryCapital Allocation
SignalHigher is better
VolatilityVolatile
First reportedQ1 2022
Last reportedQ4 2025Feb 25, 2026
How to read this metric
Provides non-dilutive or pre-planned capital; high activity may signal future changes in share count.
Detailed definition
This metric tracks cash inflows resulting from the exercise or issuance of warrants to purchase common stock. It represe...
Peer comparison
Less common than standard equity offerings; specific to companies using complex capital structures.
Metric ID:
nvda_proceeds_from_warrantsHistorical Data
4 years
| FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|
| Value | $0.00 | $0.00 | $95.42M | $0.00 |
| YoY Change | — | — | — | -100.0% |
Range$0.00 – $95.42M
Avg YoY Growth-100.0%
Median YoY Growth-100.0%
Proceeds from issuance of warrants at Other Companies
Frequently Asked Questions
- What is Revolution Medicines, Inc.'s proceeds from issuance of warrants?
- Revolution Medicines, Inc. (RVMD) reported proceeds from issuance of warrants of $0.00 in Q4 2025.
- How has Revolution Medicines, Inc.'s proceeds from issuance of warrants changed year-over-year?
- Revolution Medicines, Inc.'s proceeds from issuance of warrants decreased by 100.0% year-over-year, from $23.86M to $0.00.
- What does proceeds from issuance of warrants mean?
- Cash received from the issuance of warrants for company stock.